Wet AMD

Rapid fluid identification may result in better visual outcomes

Specialist explains approaches for a variety of cases encountered during procedure

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Analyses of IRIS Registry data capture a snapshot of patient visits and receipt of anti-VEGF injections.

Prospective randomized trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Phase 1b data show improved vision and reduced macular edema in patients, with only 3 loading doses and minimal re-treatments.

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

Investigational OCT system with AI-based image analysis holds promise

An interim analysis including data from almost 150 patients found an association between higher number of injections and increased risk of mild cognitive impairment.

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020